The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Schrodinger
Provides physics based software solutions to accelerate molecular discovery and design.
What they do
Schrodinger offers a computational physics platform that simulates molecular behavior at atomic scale. Pharmaceutical and biotechnology companies use this software to predict the properties of potential drug molecules, reducing the cost and time of early stage chemical synthesis.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Computational chemistry
- Product type
- Platform software
- Stage
- Public
- Headquarters
- New York, United States
- Region
- North America
- Founded
- 1990
- Total funding
- $410M raised
Notable investors: Bill & Melinda Gates Foundation, Deerfield Management, Baron Capital.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Beyond RECIST 1.1: The AI Endpoint Playbook for Modern Oncology Trials
Dr. Dereck Mush, MD, MBA